Datasheet

BCAS2 Antibody
CATALOG NUMBER: 5627

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:BCAS2 antibody can be used for detection of BCAS2 by Western blot at 0.5 - 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1219 - MCF7 Cell Lysate
IMMUNOGEN:BCAS2 antibody was raised against a 14 amino acid synthetic peptide near the carboxy terminus of human BCAS2.

The immunogen is located within the last 50 amino acids of BCAS2.
HOST SPECIES:Rabbit

Properties

PURIFICATION:BCAS2 Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:BCAS2 Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:BCAS2 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:BCAS2 Antibody: DAM1, SPF27, Snt309, DAM1, Pre-mRNA-splicing factor SPF27, Breast carcinoma-amplified sequence 2
ACCESSION NO.:CAG46834
PROTEIN GI NO.:49457027
OFFICIAL SYMBOL:BCAS2
GENE ID:10286

Background

BACKGROUND:BCAS2 Antibody: BCAS2 was identified through differential display analysis as an mRNA species that was overexpressed in MCF7 and BT-20 breast cancer cell lines. The chromosomal region containing this gene, 1p13.3021, is amplified in these cells lines. BCAS2 is a transcriptional cofactor that enhances estrogen receptor-mediated gene expression, and directly interacts with the tumor suppressor p53 to reduce p53 transcriptional activity by reducing p53 protein level in the absence of DNA damage. Deprivation of BCAS2 through RNA inhibition induces apoptosis in p53-wild type cells, but causes G2-M arrest in p53-null or -mutant cells; this effect was reversed with the expression of ectopic BCAS2. BCAS2 may thus be potentially useful as a therapeutic target in the treatment of cancer.
REFERENCES: 1) Nagasaki K, Maass N, Manabe T, et al. Identification of a novel gene, DAM1, amplified at chromosome 1p13.3-21 region in human breast cancer cell lines. Cancer Lett.1999; 140:219-26.
2) Qi C, Zhu YT, Chang J, et al. Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence Biochem. Biophys. Res. Commun.2005; 328:393-8.
3) Huo PC, Tsao YP, Chang HW, et al. Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor. Cancer Res.2009; 69:8877-85.

For Research Use Only